Phototherapy (UVB) and photochemotherapy (PUVA) for psoriasis

Acta Clinica Croatica

Volumn 41, Issue 2, 2002, Pages 103-112

  Kostović, Krešimir ^a   Šitum, Mirna ^a   Nola, Ivana ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Psoriasis, therapy; PUVA therapy methods, Ultraviolet therapy, adverse effects; Ultraviolet therapy, methods

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; DITHRANOL; ETRETIN; PHOTOSENSITIZING AGENT; PSORALEN; RETINOID; SALICYLIC ACID; TAZAROTENE;

CANCER RISK; CLINICAL PRACTICE; HUMAN; PHOTOCHEMOTHERAPY; PSORIASIS; PUVA; REVIEW; SKIN CANCER; SKIN DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULTRAVIOLET B RADIATION;

EID: 0036278894     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Phototherapy: UVB and PUVA
2. Phototherapy of psoriasis
3. The therapies available
4. Physical methods of therapy
5. A new development in UVB phototherapy for psoriasis
6. 311 nm UVB phototherapy D an effective treatment for psoriasis
7. 311 nm UVB lamps in the treatment of psoriasis with the Ingram regimen
8. Treatment of psoriasis with a new UVB-lamp
9. Treatment of psoriasis with a 311 nm UVB lamp
10. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B
11. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis
12. Halfside comparison study on narrow-band UV-B phototherapy vs. photochemotherapy (PUVA) in the treatment of severe psoriasis
13. Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bathwater 8-methoxypsoralen in the treatment of psoriasis
14. Diagnostic phototesting in the United Kingdom
15. Phototherapy with ultraviolet B
16. The validity and practicability of sunreactive skin types I through VI
17. The practice of ultraviolet phototherapy in the United Kingdom
18. UV phototherapy
19. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: Three times or five times weekly treatment?
20. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: A randomized study
21. Topical steroids and UV radiation in psoriasis
22. The effect on psoriasis of clobetasol propionate used alone or in combination with UVB
23. Are topical corticosteroids useful in phototherapy for psoriasis?
24. Topical salicylic acid interferes with UVB therapy for psoriasis
25. Combination therapy of psoriasis with calcipotriol and narrow band UVB
26. Combined therapy better for psoriasis than just calcipotriol
27. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris
28. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature
29. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatic combination treatment
30. Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with phototherapy: A review
31. Die Wirkskeit eines neuen Schmalspektrum-UV-B-Strahlers (Philips TL01/100 W, 311 nm) im Vergleich zur konventionellen UVB Phototherapie der Psoriasis
32. Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis
33. Clinical efficacy of narrow-band Uvb (311 nm) combined with dithranol in psoriasis. An open pilot study
34. Tazarotene in combination with phototherapy
35. Ultraviolet B phototherapy plus topical retinoid therapy
36. UVB-311-nm-phototherapie in kombination mit topischer applikation von tazaroten zur behandlung der psoriasis vulgaris
37. Calcipotriol vs tazarotene as combination therapy with narrowband ultraviolet B (311 nm): Efficacy in patients with severe psoriasis
38. Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis
39. Acitretin in combination with UVB or PUVA
40. Acitretin plus UVB therapy for psoriasis
41. Photoaging, photodamage and photoprotection
42. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study
43. Tar, ultraviolet light, PUVA, and cancer
44. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group
45. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation
46. PUVA therapy: The present state of art and perspectives
47. Phototherapy for psoriasis
48. Erythemo-papulo-squamous diseases
49. Photochemotherapy
50. Clinical pharmacokinetics of methoxsalen and other psoralens
51. An action spectrum for 8-MOP-induced sunburn cells in mammalian epidermis
52. Relative efficacy of 335 and 365 radiation in photochemotherapy of psoriasis
53. Photochemotherapy and photodynamic therapy
54. Phototesting and dosimetry for photochemotherapy
55. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA Study: A cooperative study among 18 European centres
56. Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial
57. Puva, klinik und praxis
58. British Photodermatology Group guidelines for PUVA
59. Time course of 8-methoxypsoralen-induced skin photosensitization in PUVA-bath photochemotherapy
60. Evaluation of PUVA bath phototoxicity
61. Bath-water delivery of 8-methoxypsoralen therapy for psoriasis
62. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis
63. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis
64. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis
65. Photochemotherapy of psoriasis
66. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis
67. Photochemotherapy for psoriasis remission times. Psoralens and UVA and combined photochemotherapy for psoriasis
68. Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis
69. Calcipotriol improves the response of psoriasis to PUVA
70. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid
71. Results of therapy for psoriasis using retinoid and photochemotherapy (RePUVA)
72. Phototherapy and photochemotherapy
73. Cancer induction by immunosuppression in psoriasis after heavy PUVA treatment
74. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: Response to long-term acitretin maintenance
75. PUVA therapy
76. Nail pigmentation due to oral 8-methoxypsoralen
77. 5-Methoxypsoralen (Bergapten) for photochemotherapy
78. Liver injury following administration of 8-methoxypsoralen during PUVA therapy
79. Deterioration of liver function during PUVA therapy
80. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA)
81. Ocular findings in patients treated with PUVA
82. Ocular findings in 340 longterm treated PUVA patients
83. Cutaneous and ocular side-effects of oral photochemotherapy: Results of an 8-year follow-up study
84. Ocular lens findings in patients treated with PUVA
85. UVB psoriasis, and nonmelanoma skin cancer
86. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis
87. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment
88. Long term follow up of skin cancer in the PUVA-48 Co-operative Study
89. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The photochemotherapy follow-up study
90. Cutaneous malignancy in males treated with photochemotherapy
91. 'High single-dose' European PUVA regimen also causes an excess of nonmelanoma skin cancer
92. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients
93. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study
94. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis
95. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA
96. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy
97. The risk of melanoma in association with long-term exposure to PUVA
98. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?